The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 601–669 of 669
Mohammed, S. A., Kimura, Y., Yuhki, T. O. K. U., & Ju, Y. (2022) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2022.100045
Mel, L. W. J. D. (2020) · Louisiana State University · doi:10.31390/gradschool_dissertations.5409 · Cited by 1
Isoniazid Loaded PCL-PEG Copolymer Nanoparticles for Sustained Release Application
Kulkarni, A., & Betai, P. (2023) · Recent Advances in Anti-Infective Drug Discovery · doi:10.2174/2772434418666230228121730
Modular Enzyme-Responsive Polysaccharide-Based Hydrogels for Biofabrication
Naeimipour, S. (2023) · Linköping studies in science and technology. Dissertations · doi:10.3384/9789180750349
Leitner, N. S. (2023) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/165155
Nanoparticles as Potential Agents of Chemical and Biological Weapons
(2022) · Journal of NBC Protection Corps · doi:10.35825/10.35825/2587-5728-2022-6-4-304-319
COMBINED NANOCHEMOTHERAPY USING DOXORUBICIN AND CURCUMIN AS AN EXAMPLE
Kaniuk, M. I. (2023) · Biotechnologia Acta · doi:10.15407/biotech16.01.005
FTY720-Loaded Polymeric Micelles for Treatment of Intracerebral HemorrhagePreprint
Zhou, F., Gong, X., Hu, S., He, Y., & Yang, B. (2023) · Preprints.org · doi:10.20944/preprints202307.0910.v1
Block Co-polymers: Vital Aspects and Applications in Drug Delivery
Bhayana, P., Bhat, P., Jain, R., Raina, N., Jain, A., & Sharma, T. (2023) · Springer eBooks · doi:10.1007/978-981-99-6917-3_15
Process in Honokiol Nano Formulations
(2023) · General Chemistry · doi:10.21127/yaoyigc20230010
Saha, A., Saha, R., Bandyopadhyay, S., & Gangopadhyay, M. (2023) · Journal of Survey in Fisheries Sciences · doi:10.53555/sfs.v10i1s.2306
Mohammad, S. (2023) · Research in Medical & Engineering Sciences · doi:10.31031/rmes.10.4
Sustained drug delivery to reduce the extent of burn progression
Thangaveloo, M. D. (2024) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/173605
Surface chemical functionalization of magnetic nanoparticles
Bao, Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21668-8.00005-5
High-fidelity propionaldehyde functionalized Poly(ethylene glycol): Synthesis and applications
Chen, X., Xu, G., Zhang, X., Geng, C., Wang, M., Fu, Y., Lv, Z., Wang, S., Guo, Z., & Wang, S. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113489
Penchev, H., Dimitrov, E., Novakov, C. P., Haladjova, E., Veleva, R., Moskova‐Doumanova, V., Topouzova‐Hristova, T., & Rangelov, S. (2024) · Polymers · doi:10.3390/polym16223219
“…the lack of functional groups, possible immunogenicity, and potential safety issues such as antibody formation, vacuolation, and hypersensitivity [30–32], risk of peroxidation, and last but not least, demanding synthesis using its gaseous and also toxic and highly flammable monomer ethylene…”
Defining Nanomedicine Qualities for Optimal Therapeutic Applications
Mankar, P., Saggu, G. K., Nyalkalkar, K. M., Kamble, S. C., & Mittal, S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_13
Soto, M. A. R., Rodríguez‐Gattorno, G., López, M. A. G., Cárdenas, E. M. G., Benitez, M. B. M., & Olivares‐Trejo, J. D. J. (2024) · Research Square · doi:10.21203/rs.3.rs-5397379/v1
Hot shape transformation: the role of PSar dehydration in stomatocyte morphogenesis
Peters, R., Charleston, L. A., van Eck, K., van Berlo, T., & Wilson, D. A. (2025) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.21.5
Surface modified proteins and peptides for targeted drug delivery
Chavda, V. P., & Joshi, D. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.001
Lipid Nanoparticles for Genome Editing in Hypercholesterolemia
Soroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of North Khorasan University of Medical Sciences · doi:10.32592/nkums.17.1.25
RNA Nanotechnology: Biomedical Application
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_24
PLA/PEG particles in agar hydrogels for injectable drug delivery
Zeraatkar, E., & Frounchi, M. (2025) · Chemical Papers · doi:10.1007/s11696-025-04067-8
“PEG is not a solely hydrophilic polymer, while it is known to be soluble in both polar and non-polar solvents (BunkerA 2012; Hoang Thi et al. 2020).”
Role of Polymers for Skin Disorders
Govindaswamy, B., & Kirti, P. S. (2025) · Springer tracts in additive manufacturing · doi:10.1007/978-3-031-90807-1_9
3D printing drug delivery applications in bovines
Ranjan, N., Kumar, V., Kumar, R., & Singh, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28808-1.00004-x
Sun, S., Li, Z. J., Lin, Y., Rolland, M., Nelis, T., Jin, S., Zheng, S., Raffy, B. N., Bi, W. H., Amstad, E., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202511282
Core–Shell Biopolymer Nanoparticles
Jagathjothi, N., Priya, R. S., Suresh, R., Venkatachalam, S. R., Yuvaraj, M., Saranya, M., Sharmila, R., Jayanthi, M., Arthanari, P. M., & Bharathi, C. (2025) · Smart nanomaterials technology · doi:10.1007/978-981-96-9501-0_7
Polymeric nanoparticles and fluoropyrimidine platforms in targeted cancer therapy
Pawara, P. I., Khan, M. U., Shirkhedkar, A. A., & Pawara, H. (2025) · Journal of Modern Techniques in Biology and Allied Sciences · doi:10.70604/jmtbas.v2i2.80
“PEGylated polymers can self-assemble into micelles that carry hydrophobic drugs in their core, improving solubility and half-life [22].”
Kathpalia, K. V., Verma, A. K., Mohan, A., Girdhar, M., Shankhwar, N., Malik, T., Sharma, N. R., & Kumar, A. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00875-7
“Oncas-par is also used for second-line treatment for individuals who develop hypersensitivity or neutralizing antibodies to E. coli -derived asparaginases [84].”
Phương, N. T., Nguyen, T. T. T., Thanh, H. T., Thảo, Đ. T., Can, M. V., Quoc-Long, P., Zidek, J., & Hà, L. M. (2025) · Natural Product Communications · doi:10.1177/1934578x251392004
“10,13,54,55 Notably, statistically signi fi cant differences were observed in the release rates among the three active ingredients.”
Liposomes: formulation, functionalization, properties, and their biomedical applications
Elaïssari, A., & Khizar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27406-0.00008-3
Biopolymer Mechanism: Pharmacokinetics and Pharmacodynamics
Pandey, A., & Mishra, B. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811419125010007
Sundararaman, G., & Vijayakumar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00005-1
Anand, R., & Bhattacharya, S. (2025) · International Journal of Polymeric Materials · doi:10.1080/00914037.2025.2604139
“[75] Nevertheless, PDPA nanoparticles achieve protein adsorption resistance due to the PEG poly-mer’s ability to mask foreign particle recognition by the immune system, thereby facilitating clearance.”
Rahvar, M., Manoochehrabadi, T., Marouf, B. T., Lakalayeh, G. A., Kakolvand, R., Habibi, H., & Ghanbari, H. (2026) · BioNanoScience · doi:10.1007/s12668-025-02310-w
“The decrease in surface hydrophobicity resulted from the presence of PEG, which has many hydrophilic hydroxyl groups within its structure, making it highly hydrophilic [38 ].”
InfluentialSupervised Machine Learning Implementation & Results
Ramadurai, K. W., & Banerjee, A. (2026) · SpringerBriefs in bioengineering · doi:10.1007/978-3-032-04012-1_3
Hoang, S., Dumych, T. I., Paryzhak, S. Y., Montembault, V., Fontaine, L., Passirani, C., Saulnier, P., & Krupka, O. (2026) · ACS Omega · doi:10.1021/acsomega.5c11504
Liu, S., Zhang, R., Jin, Y., Ming, Z., Li, X., & Xiang, H. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217719
Wu, E., Ding, T., Yu, Y., Liu, M., Qian, J., & Zhan, C. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.027
“Pre-existing anti-PEG antibodies represent an important factor in sLip opsonization, profoundly activating the complement system and influencing the pharmacokinetics and biodistribution of sLip, with effects that vary markedly across species 13 — 19 .”
Molecular characterisation of HIV using nanomaterials: Innovations and challenges: A review
Mohan, F. R. (2026) · AIP conference proceedings · doi:10.1063/5.0319483
Ramanoudjame, S. M. (2020) · theses.fr (ABES) · doi:10.70675/9aaefdefz6dafz4974za324zc779e3d0df04
Multifunctional nanocomposites for precise control over drug delivery
Andretto, V. (2022) · theses.fr (ABES) · doi:10.70675/7a7f57fez25f2z41a0z9072z3f3cc2aef2d6
Schulman, J. A., Arora, K., Kwiatkowski, A. J., Chada, N. C., Steele, J. A., Pagendarm, H. M., Woodworth, M. E., Sheehy, T. L., Gibson-Corley, K. N., Balko, J. M., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124238 · Cited by 1
M‐Atoom, A., Ahmed, M. H., Al-Hasnaawei, S., Malathi, H., Maharana, L., Nanda, A., Arora, V., & Singh‐Chauhan, A. (2026) · Polymer International · doi:10.1002/pi.70141
Evaluation of an Alternative Source of Power for Ship Operations in Ports
Nwaorgu, G. O., & Ogbonnaya, E. A. (2023) · JOURNAL OF ENGINEERING EMERGING TECHNOLOGIES AND APPLIED SCIENCES · doi:10.66877/jeetas.v1i1.001
Ketebu, O. (2023) · JOURNAL OF ENGINEERING EMERGING TECHNOLOGIES AND APPLIED SCIENCES · doi:10.66877/jeetas.v1i1.004
Solution properties of linear poly(glycerol): quantitative comparison with PEGs
Bae, J.-A., & Choi, S. (2026) · Polymer Journal · doi:10.1038/s41428-026-01207-z
“Accordingly, several alternatives to PEG, including poly(glycerol) (PG), poly(sarcosine) (pSar), poly(oxazoline) (POx), poly(sulfobetaine) (PSB), poly(carboxybetaine) (PCB), and poly(2-methacryloyloxyethyl phosphorylcho-line) (PMPC), have been explored [19, 20].”
Axioti, E., Berfi, N. A., Jacob, P. L., Saller, K. M., Maitland, G. L., Patel, A., Paruchuri, S., Topham, P. D., Derry, M. J., Chatterjee, S., et al. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c00647 · Cited by 1
Dynamic Arrest and Tunable Gelation of Immunogenically Inert POEGMA Nanoparticles
Sirohi, P., Ney, M. R., Shmidov, Y., Silverstein, B. E., Singh, A. A., Wadsworth, G. M., Deshpande, S., Ma, Y. Y., Fan, L., Banerjee, P. R., et al. (2026) · ACS Polymers Au · doi:10.1021/acspolymersau.6c00033
Kumar, R. R., & Enoch, I. V. M. V. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109518
Sonji, G. M., Sonji, N. M., & Katerji, A. E. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2700161
Yeshchenko, O. A., Daoud, L., Fedotov, O., Khort, P. S., & Krupka, O. (2026) · Materials Today Communications · doi:10.1016/j.mtcomm.2026.115748
Degey, M., Pedergnana, S., Évrard, B., Piel, G., Debuigne, A., & Berger, M. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2699381
Liposomes and Mixed Micelles for Improvement of Drug Solubility
Umeyor, C. E., Narula, D., Anure, A., Ezegbe, A., Kolekar, P., & Patravale, V. B. (2026) · Methods and principles in medicinal chemistry · doi:10.1002/9783527850761.ch6
Introducing hydrolytic degradability to PEG via C–H oxidation by N -chlorosuccinimide
de Fontaine, H., Wan, G., Wetzel, M., Lim, I., & Freas, D. J. (2026) · Polymer Chemistry · doi:10.1039/d6py00554c
Hulugalla, K., Fortenberry, A. W., de Silva, D. J., & Werfel, T. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04173-6 · Cited by 1
“For applications requiring repeated administration, anti-PEG immune responses can reduce efficacy over successive doses [16].”
Advances in polymeric nanoparticles for anticancer drug delivery
Hirave, K. S., Morya, N., Kumar, L., Banerjee, S., Saharan, V. A., & Singh, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44185-1.00027-6
Linking In Vivo Imaging to Therapeutic Outcome with 131I, 177Lu, 188Re Nanoparticles
Finogenova, Y. А., Lipengolts, A., Klementyeva, O., Shpakova, K. E., Skribitsky, V. А., & Grigorieva, Е. Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177856
“Alternative materials, including albumin, dextran, chitosan, and other biocompatible polymers, can modulate pharmacokinetics by governing hydrodynamic size and surface charge [56,57].”
Technological Lock-In in Advanced Drug Delivery Systems and Its Role in Translational Failure
Santos, V., Costa, R., & Teixeira, B. (2026) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/g935757564
Natanzi, A. S., Ahmadi, E., Shahraki, S., Koupaei, A. E., & Kashani, H. H. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-02049-2
“…of aptam - ers into these delivery systems typically relies on linker chemistries such as polyethylene glycol (PEG) architec - tures, which confer stealth characteristics, extend systemic circulation, and enable stimuli-responsive release through pH-sensitive or redox-cleavable linkers [ 161 –163].”
Nanoparticles Against Antimicrobial Resistance: Chemical Design, Assembly, and Emerging Applications
Vogelaar, T. D., Jenssen, H., & Lund, R. (2026) · ACS Nano · doi:10.1021/acsnano.6c09306
Jana, S., & Hoogenboom, R. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115975
Dong, Z., Wegner, A. B., Saeb, D., Kwan, M. M. C., Baerga, P. E. C., Shields, C. W., Shirts, M. R., & Sprenger, K. G. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15004571/v3
Jacob, S., Varkey, N. R., Rao, R., Shinu, P., & Khanam, R. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101314
Berthomé, Y., Coz, G.-M. L., Utard, V., Gu, Q., Fellmann-Clauss, R., Petit-Demoulière, N., Quillet, R., Gavériaux‐Ruff, C., Ramanoudjame, S. M., Estéoulle, L., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119987
Plachouras, N. V., Abedin, A., Soranidis, S., & Pitsikalis, M. (2026) · Polymers · doi:10.3390/polym18212745
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.